Sterling Capital Management LLC reduced its stake in shares of Humana Inc (NYSE:HUM) by 45.9% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 6,590 shares of the insurance provider’s stock after selling 5,580 shares during the period. Sterling Capital Management LLC’s holdings in Humana were worth $1,961,000 as of its most recent SEC filing.
Several other institutional investors also recently bought and sold shares of HUM. FMR LLC grew its holdings in shares of Humana by 12.7% during the 2nd quarter. FMR LLC now owns 12,212,514 shares of the insurance provider’s stock valued at $3,634,811,000 after acquiring an additional 1,374,030 shares in the last quarter. Old Mutual Global Investors UK Ltd. grew its holdings in shares of Humana by 213.1% during the 1st quarter. Old Mutual Global Investors UK Ltd. now owns 727,057 shares of the insurance provider’s stock valued at $195,454,000 after acquiring an additional 494,826 shares in the last quarter. Unigestion Holding SA purchased a new position in shares of Humana during the 2nd quarter valued at $79,340,000. BlackRock Inc. grew its holdings in shares of Humana by 1.7% during the 1st quarter. BlackRock Inc. now owns 12,186,387 shares of the insurance provider’s stock valued at $3,276,068,000 after acquiring an additional 198,588 shares in the last quarter. Finally, Summit Trail Advisors LLC grew its holdings in shares of Humana by 24,611.8% during the 1st quarter. Summit Trail Advisors LLC now owns 184,103 shares of the insurance provider’s stock valued at $184,000 after acquiring an additional 183,358 shares in the last quarter. Institutional investors and hedge funds own 93.00% of the company’s stock.
Several equities analysts have recently commented on HUM shares. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $326.00 price target on the stock in a report on Monday, May 21st. Citigroup restated a “buy” rating and set a $340.00 price target (up from $280.00) on shares of Humana in a report on Friday, June 1st. ValuEngine cut shares of Humana from a “buy” rating to a “hold” rating in a report on Saturday, June 2nd. BMO Capital Markets boosted their price target on shares of Humana from $328.00 to $355.00 and gave the company an “outperform” rating in a report on Monday, June 25th. Finally, Piper Jaffray Companies boosted their price target on shares of Humana from $326.00 to $350.00 and gave the company an “overweight” rating in a report on Friday, July 6th. Six analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. Humana currently has a consensus rating of “Buy” and an average price target of $331.11.
HUM stock opened at $337.24 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.43. Humana Inc has a 1 year low of $231.90 and a 1 year high of $339.88. The firm has a market capitalization of $45.68 billion, a P/E ratio of 28.80, a price-to-earnings-growth ratio of 1.65 and a beta of 0.96.
Humana (NYSE:HUM) last released its quarterly earnings data on Wednesday, August 1st. The insurance provider reported $3.96 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.17. Humana had a net margin of 2.48% and a return on equity of 17.43%. The business had revenue of $14.26 billion during the quarter, compared to analyst estimates of $14.16 billion. During the same quarter in the previous year, the business earned $3.49 EPS. equities analysts forecast that Humana Inc will post 14.18 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 26th. Investors of record on Friday, September 28th will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a dividend yield of 0.59%. The ex-dividend date of this dividend is Thursday, September 27th. Humana’s payout ratio is presently 17.08%.
In other Humana news, SVP Cynthia H. Zipperle sold 4,886 shares of the business’s stock in a transaction on Friday, August 3rd. The shares were sold at an average price of $321.89, for a total transaction of $1,572,754.54. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce D. Broussard sold 18,000 shares of the business’s stock in a transaction on Monday, September 10th. The stock was sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the transaction, the chief executive officer now directly owns 71,085 shares of the company’s stock, valued at approximately $23,362,796.10. The disclosure for this sale can be found here. In the last ninety days, insiders sold 51,752 shares of company stock valued at $16,581,234. 0.60% of the stock is owned by company insiders.
Humana Company Profile
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Recommended Story: Stock Symbols Definition, Examples, Lookup
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.